durvalumab
Sign in to saveAlso known as MEDI4736, MEDI-4736, Imfinzi
Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that binds to programmed cell death ligand 1 (PD-L1) on cancer cells and blocks interactions with PD-1 and CD80 (B7.1) on T cells.
Key facts
- Drug.type
- mab
- Drug.image
- Durvalumab PD-L1 5X8M.pdb.png
- Drug.caption
- Antigen-binding fragment of durvalumab (pale green) in complex with PD-L1 (pink). .
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- CD274
- Drug.tradename
- Imfinzi
- Drug.MedlinePlus
- a617030
- Drug.DailyMedID
- Durvalumab
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- FF03
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- /Schedule D
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 3 more facts
- World Health Organisation international non-proprietary name
- durvalumab
- subject has role
- monoclonal antibody
- physically interacts with
- CD274 molecule
via Wikidata · CC0
~14 min read
Encyclopedic overview
11 sectionsContents
- Medical uses
- History
- Clinical trials
- MYSTIC
- PACIFIC
- CASPIAN
- TOPAZ-1
- DUO-E
- AEGEAN
- WHO Confirmation of Falsified IMFINZI
- References
Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that binds to programmed cell death ligand 1 (PD-L1) on cancer cells and blocks interactions with PD-1 and CD80 (B7.1) on T cells.
Durvalumab is an immune checkpoint inhibitor drug. It was approved in for medical use in the United States in May 2017, and in the European Union in September 2018.
Excerpted from Wikipedia’s “durvalumab” article, available under the CC BY-SA 4.0 licence.